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take into account the impact on quality of life (QOL)6-9 in
addition to clinical outcomes such as symptoms.
To date, the few studies that have assessed QOL in
patients with varicose veins by the use of standardized and
scientifically rigorous instruments8 have produced con-
flicting results. Two postal surveys that used the Short-
Form Health Survey-36 (SF-36) found that patients with
varicose veins reported significantly poorer QOL than
general population control subjects,10 but better QOL
than patients with low back pain, menorrhagia, and sus-
pected peptic ulcer.11 Other studies that have used the SF-
3612,13 and a disease-specific measure12 reported no
significant differences in QOL between patients with vari-
cose veins and the general population.
One explanation of these contradictory results is that
no earlier studies have adjusted for the effect of concomi-
tant venous disorders of the leg, such as edema, skin
changes, and ulceration, that are frequently associated
with varicose veins.14 Because symptoms and impaired
QOL15-17 may also be the result of concomitant venous
disease, it is unknown whether outcomes are attributable
to varicose veins per se or to concomitant venous disease
of the leg.
We evaluated symptoms and QOL in an international,
population-based study of patients with varicose veins, by
using generic and disease-specific QOL measures. To
Varicose veins are one of the most common medical
conditions in the Western world. The estimated preva-
lence of visible tortuous veins in individuals older than 15
years has been estimated at 10% to 15% in men and 20%
to 25% in women.1 The cost of surgical treatment for the
health system is therefore a matter of concern for many
regulatory authorities.2-4 A recent population-based study
in Scotland found a poor agreement between symptoms
and severity of varicose veins, especially in men.5 However,
it is now widely recognized that the evaluation of disease
burden in chronic conditions such as varicose veins must
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Purpose: This study assessed the impact of varicose veins (VV) on quality of life (QOL) and patient-reported symptoms.
Methods: A cross-sectional population-based study was held in 166 general practices and 116 specialist clinics for venous
disorders of the leg in Belgium, Canada (Quebec), France, and Italy. Study subjects included a sample of 259 reference
patients without VV (CEAP class 0 or 1) and 1054 patients with VV who were classified as having VV alone (367;
34.8%), VV with edema (125; 11.9%), VV with skin changes (431; 40.9%), VV with healed ulcer (100; 9.5%), and VV
with active ulcer (31; 2.9%). The main outcome measure was generic and disease-specific QOL, as measured by means
of the Short-Form Health Survey-36 (SF-36) and the VEINES-QOL scale, and patient-reported symptoms as mea-
sured by the VEINES-SYM scale.
Results: In patients with VV, age-standardized mean SF-36 physical (PCS) and mental (MCS) scores were 45.6 and 46.1
in men and 44.2 and 43.2 in women, respectively, compared with population norms of 50. PCS scores decreased
according to increasing severity of concomitant venous disease, with the lowest mean scores of 37.3 and 35.5 found in
patients with VV and active ulcer. However, adjusted analyses showed no statistically significant differences between
patients with VV alone and patients without VV for PCS (0.0), MCS (1.0), VEINES-QOL (–0.1), or VEINES-SYM
(0.0) scores. In comparison with patients without VV, the largest differences were seen in patients with VV and edema
(PCS, VEINES-QOL, and VEINES-SYM score differences of –1.8, –2.5, and –2.9, respectively) and in patients with
VV and ulceration (differences of –3.3, –3.4, and –2.7, respectively). The high prevalence of major symptoms of venous
disorders in patients in CEAP class 0 or 1 being treated for venous disorders (76.1% of patients had heaviness, aching
legs, or swelling) might have contributed to the impairment of QOL in the reference group.
Conclusion: Results indicate that impairment in physical QOL in patients with VV is associated with concomitant
venous disease, rather than the presence of VV per se. Findings concerning QOL in patients with VV can only be reli-
ably interpreted when concomitant venous disease is taken into account. In patients with VV alone, the objectives of
cosmetic improvement and the improvement of QOL should be considered separately. (J Vasc Surg 2001;34:641-8.)
study the association between outcomes and varicose veins
per se, we compared patients with varicose veins alone or
in combination with concomitant venous disorders of the
leg and patients without varicose veins. Our analyses are
based on data from the Venous Insufficiency
Epidemiological and Economical Study (VEINES).18
METHODS
Study design. The VEINES study was an interna-
tional, prospective cohort study carried out from 1994 to
1997. The main objective of the study was to compare
clinical outcomes, QOL, costs, and use of health services
in patients with chronic venous disorders of the leg
(CVDL).18 The study population was based on a prospec-
tive registration of 5688 consecutive outpatients, 18 to 75
years old, who consulted 166 general practitioners and
116 specialists in venous disorders in Belgium, Canada
(Quebec), France, and Italy. The choice of these countries
was guided by means of the socioeconomic part of the
study. Data recorded at registration included age, sex, and
symptoms and signs of venous disorders of the leg. All
men and all patients with an active leg ulcer were entered
into the study. The remaining study patients were ran-
domly sampled among the other registered patients, with
the aim of recruiting 1600 patients in the four countries.
Patients who consented to participate were invited to a
baseline visit, which included a medical history and physi-
cal examination by the clinician. To obtain independent
evaluations of patient-reported QOL and symptoms and
physician-based clinical status, we mailed QOL question-
naires to patients for completion before the baseline visit.
This study reports on baseline assessments of QOL and
clinical data only for the subgroup of patients in the
VEINES study with varicose veins, compared with a refer-
ence group of patients without varicose veins.
Clinical classification. Patients with varicose veins
were identified at the baseline visit by means of clinical
diagnosis on the basis of the assessment of the signs of
varicose veins (ie, the presence of dilated, elongated, or
tortuous veins on either leg). Patients were classified as
having (1) varicose veins alone, (2) varicose veins and
venous edema, (3) varicose veins and skin changes, (4)
varicose veins and healed ulcer, and (5) varicose veins and
active ulcer. Each category could include signs present in
a lower order category (eg, edema could be present in the
category “varicose veins and skin changes”). A reference
group of patients without varicose veins was defined by
selecting patients in class 0 (no physical signs of venous
disorders) or class 1 (presence of telangiectasias or reticu-
lar veins only on either leg) of the international CEAP
classification.19
A history of thrombophlebitis was reported by clini-
cians at the baseline visit. Specialists were asked to specify
the anatomical segment(s) affected by varicose veins: short
saphenous, long saphenous, or nonsaphenous. They also
had to provide a global rating of the severity of varicose
veins by choosing one of these categories: mild, moderate,
severe, very severe (categories “severe” and “very severe”
were pooled in the analysis because of the small number of
observations in the “very severe” category).
Quality of life and patient-reported symptoms.
Self-administered generic and disease-specific instruments
were used as a means of measuring QOL. We used the
generic Short-Form Health Survey-36 (SF-36) to measure
physical (PCS) and mental (MCS) QOL.20 High scores
indicated good QOL. We also used the VEINES-QOL, a
disease-specific measure of CVDL-related QOL and symp-
toms that was developed as a part of the VEINES study.21
The 26-item questionnaire includes 10 items on symptoms
of CVDL (heavy legs, aching legs, swelling, night cramps,
heat or burning sensation, restless legs, throbbing, itching,
and tingling sensation), 9 items on limitations in daily
activities caused by CVDL, 5 items on psychological
impact, and 2 items on changes in the past year and time
during the day of highest symptom intensity. Four lan-
guage versions (English, French, French Canadian, and
Italian) were developed and evaluated in field testing
involving 615 patients in four countries. Results confirmed
the acceptability (item nonresponse, item endorsement fre-
quencies, item/scale floor and ceiling effects), reliability
(internal consistency, item-total and inter-item correla-
tions, test-retest reliability), validity (content, construct,
convergent and discriminant validity, known groups), and
responsiveness of the four language versions.21 The
VEINES-QOL produces two summary scores: the
VEINES-QOL provides an overall estimate of QOL, and
the VEINES-SYM provides an overall estimate of CVDL
symptom frequency. High scores indicate good QOL.
Statistical analysis. A dichotomous variable was cre-
ated to indicate the presence or absence of at least one of
three major patient-reported venous symptoms on either
leg (heaviness, aching legs, swelling). In descriptive analy-
ses, standard statistical tests (χ2 test and analysis of vari-
ance) were used as a means of comparing the distribution
and the mean values of a patient variable by clinical cate-
gory. Mean scores for SF-36 PCS, SF-36 MCS, VEINES-
QOL, and VEINES-SYM were computed separately by
sex and clinical classification. To estimate QOL in a repre-
sentative population of patients who were consulting clin-
icians, we standardized results for men and women in each
clinical category by age (18-59 and 60-75 years), with the
age distribution of registered patients in the same category
as the standard.22 Scores for all patients with varicose veins
were also standardized according to the distribution of
registered patients by clinical class of varicose veins.
Analysis of covariance23,24 was used as a means of estimat-
ing adjusted differences in PCS, MCS, VEINES-QOL,
and VEINES-SYM scores between patients with varicose
veins and patients without varicose veins. Analysis of vari-
ance was used in preliminary analyses as a means of meas-
uring the strength of association between QOL and each
of the these variables: sex, age, body mass index, educa-
tion, comorbidity (measured by the presence of at least
one of these clinician-reported diseases: cardiac disease,
chronic respiratory disease, diabetes mellitus, severe
hepatic disorder, hypertension, hypothyroidism, lymph-
JOURNAL OF VASCULAR SURGERY
642 Kurz et al October 2001
edema, osteoarthritis, peripheral arterial insufficiency of
the lower legs, renal insufficiency), country, and type of
physician (specialist or general practitioner). A P value less
than .10 was the criterion used as a means of identifying
potential confounders to be adjusted for in covariance
analyses. Age and sex were forced into all final models.
Because of missing values, the sample size was reduced in
models that included education and body mass index.
Two categories in the clinical classification, “varicose veins
and healed ulcer” and “varicose veins and active ulcer,”
were pooled in the covariance analyses to increase the sam-
ple size in the group of patients with varicose veins and
ulcer. Statistics are reported as mean difference scores
between patients with varicose veins and patients without
varicose veins and 95% CIs.
Sensitivity analyses were carried out on the subsample
of patients recruited by specialists to determine the effect
of a possible misclassification in the diagnosis of CVDL by
general practitioners. This analysis also allowed us to test
whether the extent of varicose veins (measured by means
of the number of affected anatomical segments and the
rating of severity of varicose veins) could explain differ-
ences in QOL between patients with varicose veins alone
and patients with varicose veins and concomitant venous
disorders (edema, skin change, or ulceration). For this
purpose, the number of affected segments was represented
by a variable with two categories: (1) only one affected
segment and (2) two or more affected segments. The asso-
ciation of this variable and of the severity of varicose veins
with QOL scores was first tested with analysis of variance.
In case of an association with one of the QOL variables
(on the basis of P < .10), a covariance analysis with
patients who had varicose veins alone as the reference
group was used as a means of comparing differences in
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QOL scores in models with and without the variable indi-
cating the extent of varicose veins.
RESULTS
Of 5688 study subjects with CVDL who were regis-
tered in 166 general practices and 116 specialist clinics,
1531 were recruited into the VEINES study, including
484 subjects in Belgium, 95 in Canada (Quebec), 593 in
France, and 359 in Italy. Of these, 218 had edema, skin
changes, or ulceration without varicose veins and were not
included in the study population. The remaining 1313
subjects included 259 reference patients without varicose
veins and 1054 patients with varicose veins. Patients with
varicose veins were classified as follows: 367 (34.8%) with
varicose veins alone, 125 (11.9%) with varicose veins and
edema, 431 (40.9%) with varicose veins and skin changes,
100 (9.5%) with varicose veins and healed ulcer, and 31
(2.9%) with varicose veins and active ulcer. Among
patients without varicose veins, 58 (22.4%) were in class 0
and 201 (77.6%) were in class 1 of the CEAP classifica-
tion. The numbers of study patients recruited by special-
ists and general practitioners were 483 (36.8%) and 830
(63.2%), respectively.
Characteristics of the study population are shown in
Tables I and II. Heaviness, aching, or swelling was
reported by 76.1% of patients in the reference group. The
proportion of patients with varicose veins who reported at
least one of these symptoms was 85.8% (82.7% of men,
86.9% of women). A history of thrombophlebitis was
reported in 22.2% of all patients. This percentage was
47.0% for patients with varicose veins and skin changes
and 58.1% for patients with varicose veins and active ulcer.
The use of bandages, stockings, or tights was mentioned
by 28.0% of patients, ranging from 14.3% (no varicose
Table I. Characteristics of study population
VV and VV and VV and VV and
No VV VV alone edema skin changes healed ulcer active ulcer
N 259 367 125 431 100 31
Sex*
Men 23 (8.9) 90 (24.5) 21 (16.8) 120 (27.8) 31 (31.0) 15 (48.4)
Women 236 (91.1) 277 (75.5) 104 (83.2) 311 (72.2) 69 (69.0) 16 (51.6)
Mean age (SEM)† 43.5 (0.8) 50.4 (0.7) 55.5 (1.3) 60.6 (0.5) 62.1 (1.1) 63.5 (2.0)
Symptoms
Heaviness 165 (63.7) 279 (76.0) 98 (78.4) 335 (77.7) 85 (85.0) 22 (71.0)
Aching legs 148 (57.1) 249 (67.8) 91 (72.8) 302 (70.1) 78 (78.0) 24 (77.4)
Swelling 94 (36.3) 155 (42.2) 90 (72.0) 259 (60.1) 71 (71.0) 16 (51.6)
Any 197 (76.1) 303 (82.5) 114 (91.2) 368 (85.4) 93 (93.0) 26 (83.9)
History of thombophlebitis* 20 (7.7) 51 (13.9) 31 (24.8) 125 (29.0) 47 (47.0) 18 (58.1)
Compression therapy
Bandages 5 (1.9) 4 (1.1) 2 (1.6) 20 (4.6) 14 (14.0) 13 (41.9)
Stockings 10 (3.9) 30 (8.2) 10 (8.0) 77 (17.9) 30 (30.0) 6 (19.4)
Tights 19 (7.3) 34 (9.3) 20 (16.0) 54 (12.5) 13 (13.0) 2 (6.5)
Type not specified 4 (1.5) 2 (0.5) –– 1 (0.2) 1 (1.0) 1 (3.2)
Any* 37 (14.3) 69 (18.8) 32 (25.6) 151 (35.0) 56 (56.0) 22 (71.0)
With the exception of age, figures are numbers of patients with percentages in parentheses.
*P < .05 for the test of differences in variable distribution by clinical category.
†P < .05 for the test of differences in mean age by clinical category.
VV, Varicose veins.
veins) to 71.0% (varicose veins and ulcer). The severity of
varicose veins as assessed by specialists increased with the
severity of concomitant venous disorders. About 50% of
patients with a healed or active ulcer had varicose veins
rated as severe or very severe. The long saphenous and
nonsaphenous anatomical segments were the venous seg-
ments most frequently affected by varicose veins (59.6%
and 61.2%, respectively).
Because of missing values for some items, SF-36 PCS
and MCS, VEINES-QOL, and VEINES-SYM scores were
available for 1135 (86.4%), 1234 (94.0%), and 1224
(93.2%) patients, respectively. In patients with varicose
veins, age-standardized mean PCS and MCS scores were
45.6 and 46.1, respectively, in men and 44.2 and 43.6,
respectively, in women, compared with population norms
of 50. Age-standardized mean scores for sex and clinical
category are shown in Table III. Whereas there is no clear
relationship between MCS scores and clinical category for
either men or women, PCS scores decreased according to
increasing severity of concomitant disease in both men and
women (eg, difference in scores of 10 between patients
with varicose veins alone and patients with varicose veins
and active ulcer). VEINES-QOL and VEINES-SYM
scores show a similar pattern (Table IV). Age-standardized
mean scores in patients with varicose veins were 50.7 and
50.3, respectively, in men and 49.0 and 49.1, respectively,
in women. VEINES-QOL and VEINES-SYM scores were
lower in men than in women in all clinical classes.
No significant differences in PCS scores between
patients with varicose veins alone and patients without
varicose veins (difference, 0.0; 95% CI, –1.6 to 1.6) were
shown by means of adjusted covariance analyses (Table V).
In the other clinical classes, the largest difference in mean
PCS scores was found between patients with varicose veins
and healed or active ulcers and patients without varicose
veins (–3.3; 95% CI, –5.6 to –1.0). The difference in mean
PCS scores between patients with varicose veins and
edema and patients without varicose veins approached,
but did not reach, statistical significance (–1.8; 95% CI,
–4.0 to 0.4). There were no differences in MCS scores
between patients with varicose veins in any of the clinical
categories and patients without varicose veins.
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Table II. Extent of varicose veins measured in patients recruited by specialists
VV and VV and VV and VV and
VV alone edema skin changes healed ulcer active ulcer
N 128 35 118 37 9
Severity of VV*
Mild 55 (43.0) 8 (22.8) 18 (15.3) 5 (13.5) 2 (22.2)
Moderate 60 (46.9) 25 (71.4) 65 (55.1) 14 (37.8) 2 (22.2)
Severe/very severe 12 (9.4) 1 (2.9) 33 (28.0) 18 (48.7) 5 (55.6)
Unknown 1 (0.7) 1 (2.9) 2 (1.7) –– ––
Affected segment
Unknown 3 (2.3) 1 (2.9) 6 (5.1) –– ––
Short saphenous 10 (7.8) 5 (14.3) 18 (15.2) 8 (21.6) 0
Long saphenous 75 (58.6) 20 (57.1) 73 (61.9) 21 (56.8) 6 (66.7)
Nonsaphenous 72 (56.2) 25 (71.4) 74 (62.7) 24 (64.9) 5 (55.6)
Segments affected*
Only 1 97 (75.8) 19 (54.3) 65 (55.1) 23 (62.2) 7 (77.8)
≥ 2 28 (21.9) 15 (42.8) 47 (39.8) 14 (37.8) 2 (22.2)
With the exception of age, figures are numbers of patients with percentages in parentheses.
*P < .05 for the test of differences in variable distribution by clinical category.
VV, Varicose veins.
Table III. Age-standardized SF-36 mental and physical component scores, by sex and clinical category
VV and VV and VV and VV and
No VV VV alone edema skin changes healed ulcer active ulcer
Men
n 19 80 18 106 27 11
MCS mean (SEM) 47.2 (2.2) 46.2 (0.9) 46.8 (2.4) 45.2 (1.0) 46.2 (1.9) 53.8 (2.4)*
PCS mean (SEM) 45.6 (2.1) 47.6 (1.0) 48.0 (2.3) 45.4 (0.9) 42.9 (1.7) 37.3 (2.5)
Women
n 205 249 89 254 63 14
MCS mean (SEM) 43.0 (0.8) 43.9 (0.5) 41.8 (1.3) 44.5 (0.7) 40.9 (1.5) 43.4 (3.4)
PCS mean (SEM) 48.3 (0.6) 46.5 (0.5) 43.6 (1.0) 43.6 (0.6) 39.4 (1.2) 35.5 (2.7)
*Estimate based on one patient younger than 60 years and 10 patients 60 years or older.
VV, Varicose veins; MCS, mental component score; PCS, physical component score.
Results of the adjusted analyses for VEINES-QOL
and VEINES-SYM scores are comparable with those for
PCS (Table VI). The difference in VEINES-QOL scores
between patients with varicose veins alone and patients
without varicose veins was –0.1 (95% CI, –1.1 to 0.9).
The largest difference in mean VEINES-QOL scores was
found in patients with varicose veins and healed or active
ulcers compared with patients without varicose veins
(–3.4; 95% CI, –4.9 to –1.9). The largest differences in
mean VEINES-SYM scores were found in patients with
varicose veins and edema (–2.9; 95% CI, –4.5 to –1.3) or
ulcer (–2.7; 95% CI, –4.4 to –1.0) compared with patients
without varicose veins.
Comparable results were produced by means of sensi-
tivity analyses performed in the subgroup of patients
recruited by specialists. The adjusted differences in mean
PCS, MCS, VEINES-QOL, and VEINES-SYM scores
between patients with varicose veins alone and patients
without varicose veins were –0.1, 2.1, 0.2, and –0.1, respec-
tively. None of these differences was statistically different
from zero. In comparison with reference patients without
varicose veins, the largest differences in PCS and VEINES-
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QOL scores were found in patients with varicose veins and
ulcer (–3.8 and –3.9, respectively) and in VEINES-SYM
scores in patients with varicose veins and edema (–4.2). In
patients recruited by specialists, the number of segments
affected was associated with concomitant venous disorders
(Table I). However, no statistically significant association
was found between this variable and any of the four QOL
scores used in the study. The severity of varicose veins was
significantly associated only with VEINES-QOL (P < .01).
In the analysis of covariance with patients with varicose veins
alone as the reference group and including severity of vari-
cose veins as a covariate, the difference in VEINES-QOL
was –2.5 for patients with varicose veins and edema, –1.2 for
patients with varicose veins and skin changes, and –3.1 for
patients with varicose veins and ulcer. These estimates were
–2.5, –1.7, and –4.0, respectively, in a model in which sever-
ity of varicose veins was omitted. These results suggest that
the extent of varicose veins could explain part of the differ-
ence in VEINES-QOL in patients with varicose veins and
concomitant venous disorders. This contribution would be
modest and not exceed 25% of the total score difference for
patients with varicose veins and healed or active ulceration.
Table IV. Age-standardized mean VEINES-QOL and VEINES-SYM scores, by sex and clinical category
VV and VV and VV and VV and
No VV VV alone edema skin changes healed ulcer active ulcer
VEINES-QOL in men
n 21 87 20 116 30 13
Mean (SEM) 51.9 (1.1) 52.6 (0.6) 51.5 (1.4) 50.2 (0.5) 48.5 (1.1) 46.9 (1.5)
VEINES-SYM in men
n 22 87 19 114 30 12
Mean (SEM) 52.2 (1.1) 52.3 (0.6) 48.9 (1.8) 49.4 (0.6) 48.8 (1.2) 50.3 (1.3)
VEINES-QOL in women
n 222 259 97 288 67 16
Mean (SEM) 52.0 (0.3) 50.8 (0.3) 47.8 (0.6) 48.7 (0.4) 45.5 (0.8) 43.1 (1.7)
VEINES-SYM in women
n 220 260 95 284 66 15
Mean (SEM) 52.1 (0.4) 50.9 (0.4) 47.6 (0.7) 48.7 (0.4) 45.9 (0.9) 45.4 (2.1)
VV, Varicose veins.
Table V. Adjusted mean SF-36 physical and mental scores and differences by category of the clinical classification
(adjusted covariance analysis)
SF-36 PCS* SF-36 MCS†
Difference Difference
Clinical classification n Mean (95% CI) n Mean (95% CI)
1: No signs or telangiectasia alone 194 46.5 0.0 224 45.4 0.0
2: VV alone 284 46.5 0.0 (–1.6 to 1.6) 329 46.4 1.0 (–0.9 to 2.9)
3: VV and venous edema 89 44.7 –1.8 (–4.0 to 0.4) 107 44.9 –0.5 (–3.1 to 2.1)
4: VV and skin changes 322 46.3 –0.2 (–1.9 to 1.5) 360 45.9 0.5 (–1.5 to 2.5)
5/6: VV and healed or active ulcer 100 43.2 –3.3 (–5.6 to –1.0) 115 45.4 0.0 (–2.7 to 2.7)
*Results adjusted for sex, age, body mass index, educational level, comorbidity, country, and type of physician; n = 989 because of missing values for some
of the variables.
†Results adjusted for sex, age, country, and type of physician; n = 1135.
VV, Varicose veins; PCS, physical component score; MCS, mental component score.
DISCUSSION
Varicose veins represent a chronic condition that may
have an impact on QOL. Earlier research, however, has
not examined the effect of varicose veins per se, separately
from the effect of concomitant venous disorders of the
leg. Results from this study indicate that 65.2% of patients
with varicose veins also have concomitant venous diseases
such as edema, skin changes, or ulcers. Because concomi-
tant venous diseases may also be associated with symptoms
and impaired QOL,14-17,25 they should be taken into
account when evaluating the impact of varicose veins on
QOL. The average SF-36 PCS score for women with vari-
cose veins ranged from 47.6 in patients with varicose veins
alone to 37.3 in patients with varicose veins and ulcer.
Comparable findings were observed for VEINES-QOL
and VEINES-SYM scores. Therefore, findings on QOL
are meaningful only if they are interpreted in relation to
the presence or absence of concomitant venous disorders.
Results show that impairment in physical QOL is asso-
ciated with concomitant disease, rather than the presence
of varicose veins per se. This is particularly apparent when
the concomitant disease is a healed or active ulcer. The
extent of impairment associated with ulcers is evident
through a comparison of SF-36 scores in our sample and
US norms. For example, compared with US norms, PCS
scores for patients with varicose veins and ulcer (37.5 in
men, 35.5 in women) are similar to scores in patients who
have limitations in the use of an arm or a leg (37.7) and
lower than scores in patients with chronic lung disease
(42.3), back pain (43.1), or arthritis (43.2).20 These data
are consistent with findings of other studies that showed
impaired QOL in patients with chronic leg ulcera-
tion.15,26,27 These results were confirmed by means of
findings based on the VEINES-QOL , a disease-specific
measure of QOL that provides scores that are more sensi-
tive to the combination of venous disorders with varicose
veins than those provided by the SF-36. In comparison
with patients without varicose veins, statistically significant
differences in VEINES-QOL and VEINES-SYM scores
were observed for patients in all clinical classes, except
patients with varicose veins alone. More severe varicose
veins in patients with concomitant venous disorders could
explain part of the difference in QOL. Results from
patients recruited by specialists suggest that this effect is
likely to exist only for the specific VEINES-QOL scale and
would explain only a small proportion of the observed dif-
ferences. The second conclusion that can be derived from
results on physical QOL is that patients in CEAP class 0 or
1 have a deterioration of QOL that is equal to those
patients who have varicose veins alone.
Although there is also evidence of impairment in
mental QOL, particularly in women with varicose veins
alone and women with concomitant disease, this was true
even for the reference group of patients without varicose
veins. Compared with US norms (50.0),20 MCS scores
for women without varicose veins (43.0), women with
varicose veins alone (43.9), and women with varicose
veins with concomitant disease (40.9 to 44.5) were statis-
tically (P < .05) and clinically significant. The differences
were less pronounced in men. These findings suggest
that, in women only, the entire range of venous diseases
of the leg, including conditions with symptoms or telan-
giectasias only, or with varicose veins with and without
concomitant disease, is associated with compromised
mental QOL.
Study limitations might explain the lack of difference
in QOL between patients with varicose veins alone and
patients without varicose veins. The study sample was
based on patients who consulted clinicians for chronic
venous disorders of the leg. The reference group of
patients without varicose veins included patients in classes
0 and 1 of the CEAP classification, 77.6% of whom were
in class 1. This large proportion of patients with telan-
giectasia in patients without varicose veins could reduce
the difference in QOL scores between patients with vari-
cose veins and patients without varicose veins. However, a
high prevalence of telangiectasia or reticular veins is not
unusual and has also been found in the Scottish general
population (> 80%).28 Moreover, we are unaware of data
showing an effect of telangiectasia on symptoms or QOL.
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Table VI. Adjusted mean VEINES-QOL and VEINES-SYM scores and differences by category of the clinical classifi-
cation (adjusted covariance analysis) 
VEINES-QOL* VEINES-SYM*
Clinical classification n Mean Difference (95% CI) n Mean Difference (95% CI)
1: No signs or telangiectasia alone 208 51.7 0.0 207 51.4 0.0
2: VV alone 301 51.6 –0.1 (–1.1 to 0.9) 301 51.4 0.0 (–1.2 to 1.2)
3: VV and venous edema 96 49.2 –2.5 (–3.9 to –1.1) 95 48.5 –2.9 (–4.5 to –1.3)
4: VV and skin changes 361 50.3 –1.4 (–2.5 to –0.3) 355 49.9 –1.5 (–2.8 to –0.2)
5/6: VV and healed or active ulcer 109 48.3 –3.4 (–4.9 to –1.9) 108 48.7 –2.7 (–4.4 to –1.0)
*Results adjusted for sex, age, body mass index, educational level, comorbidity, country, and type of physician; n = 1075 (VEINES-QOL) and 1066
(VEINES-SYM) because of missing values for some of the variables.
VV, Varicose veins.
The high prevalence of any of three major symptoms of
venous disorders (heaviness, aching legs, swelling) in the
reference group (76.1%) might explain impairment of
QOL among these patients. This effect would, however,
not account for large differences in QOL scores between
patients with varicose veins and ulcer and patients in other
clinical categories (eg, varicose veins and edema), despite
similar prevalence of major symptoms (> 90%).
We cannot exclude the possibility that telangiectasia or
reticular veins have been misclassified as varicose veins,
and vice versa, resulting in a reduction of differences in
QOL scores between patients with varicose veins alone
and patients without varicose veins. However, the sensitiv-
ity analyses performed in the subsample of patients
recruited by specialists, who are less likely to misclassify
varicose veins, showed differences in PCS, MCS,
VEINES-QOL, and VEINES-SYM scores of –0.1, 2.1,
0.2, and –0.1, respectively. These results are consistent
with those for all patients. We cannot exclude the possi-
bility that the SF-36 and VEINES-QOL scales were not
sensitive enough measures for detecting small but relevant
differences between groups in aspects such as cosmetic
appearance or domains of QOL not assessed by these
questionnaires. Further research is needed to identify such
domains and assess the impact of varicose veins.
Bradbury et al5 have shown that the age-adjusted
prevalence of symptoms did not differ with the presence
and severity of trunk and hyphenweb varices, especially in
men. This study provides additional evidence, showing
that impairments in QOL are only evident in patients with
varicose veins who have concomitant venous disorders,
such as venous edema or ulcers. These findings have impli-
cations for the treatment of patients with varicose veins. In
patients with varicose veins, the objectives of cosmetic
improvement and improvement of QOL (including relief
of symptoms) should be considered separately. In patients
with varicose veins alone without concomitant disease, it
may be useful to investigate other medical causes of symp-
toms and QOL impairment. Controlled clinical trials are,
nevertheless, still needed as a means of evaluating the
impact of varicose vein treatments on important patient-
based outcomes such as QOL and symptoms.
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Unit, London School of Hygiene and Tropical Medicine,
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